Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Akero Therapeutics Inc.

Clear Street analyst Kaveri Pohlman maintained a Hold rating on Akero Therapeutics yesterday and set a price target of $54.00. The company’s shares...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AKRO	$54.31	+0.15%	1.12M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AKRO	$54.31	+0.1%	1.12M
3
4
5
6

AKRO

AKRO

Get Akero Therapeutics Inc. Data in Excel

Get Akero Therapeutics Inc. Data in Excel